Pharmacy

AML: mutant IDH1 inhibitor HMS-101

MM: The battle for new drugs

The need for academic and pharmaceutical collaboration in drug development

Self-administration of bortezomib in multiple myeloma: results from Cardiff

Accelerating clinical trials in transplantation

Regulatory approval of CPX-351 for secondary AML

CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML

The switch to biosimilar rituximab at UCH: 12 months on

Patient education is important for drug tolerance and adherence

The role of the pharmacist in transplant

A pharmacoeconomic analysis of multiple myeloma treatment

Value and cost in MM treatment

Subcutaneous daratumumab: combining efficacy, safety & convenience

The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib

Ruxolitinib and ibrutinib: the future for GvHD treatment?

Treating GvHD: current challenges and newly approved drugs